Bio-Rad Laboratories 경영진
경영진 기준 점검 4/4
Bio-Rad Laboratories CEO는 Norman Schwartz, Jan2003 에 임명되었습니다 의 임기는 23.67 년입니다. 총 연간 보상은 $8.00M, 13.6% 급여 및 86.4% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $450.81M 가치에 해당하는 회사 주식의 4.58% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 2.5 년과 9.4 년입니다.
핵심 정보
Norman Schwartz
최고경영자
US$8.0m
총 보수
| CEO 급여 비율 | 13.63% |
| CEO 재임 기간 | 23.7yrs |
| CEO 지분 보유율 | 4.6% |
| 경영진 평균 재임 기간 | 2.5yrs |
| 이사회 평균 재임 기간 | 9.4yrs |
최근 경영진 업데이트
Recent updates
Seeking Alpha • Sep 10
Bio-Rad: Favorable Read-Across From Investor Event
Summary Bio-Rad Laboratories remains a Buy, after my assessment of relevant corporate disclosures at the recent Wells Fargo Healthcare conference. Management targets long-term operating margins of 20%, with intermediate milestones in the mid-teens, outpacing consensus expectations. Margin drivers include cost rationalization, AI-driven efficiencies, and a shift toward higher-margin consumables revenue. The catalysts relating to ongoing activist engagement and R&D leverage are still intact. Read the full article on Seeking Alpha
내러티브 업데이트 • Sep 03
BIO: Buybacks And Flat 2026 Outlook Will Shape Future Returns
Analysts have lifted their price target on Bio-Rad Laboratories from $370 to $390 as they refresh their models for discount rate, revenue growth, profit margin, and future P/E assumptions. What’s in the News for Bio-Rad Laboratories Bio-Rad Laboratories issued earnings guidance for the third quarter of 2026 and expects revenue to be flat compared with the second quarter, which the company describes as a typical pattern for its business.
내러티브 업데이트 • Aug 20
BIO: Buybacks Will Likely Mask Flat Near‑Term Revenue Trend
Analysts have raised their price target on Bio-Rad Laboratories from $293 to $329, citing updated assumptions on revenue growth, profit margins, and future P/E levels that feed into their valuation models. What’s in the News for Bio-Rad Laboratories Bio-Rad Laboratories issued earnings guidance for the third quarter of 2026, indicating that revenue is expected to be flat compared with the second quarter.내러티브 업데이트 • Aug 06
BIO: Activist Pressure And Flat Near-Term Outlook Will Shape Future Returns
Analysts have lifted their price target on Bio-Rad Laboratories from $320 to $370, citing updated assumptions for revenue growth, profit margins, and future P/E as key drivers of the revised valuation framework. What’s in the News for Bio-Rad Laboratories Bio-Rad Laboratories issued earnings guidance for the third quarter of 2026 and indicated that revenue is expected to be flat compared with the second quarter, which it described as a typical pattern for the company.
내러티브 업데이트 • Jul 02
BIO: Fair Outlook Will Balance Activist Pressure Against Refined Return Assumptions
Analysts have reduced their price target on Bio-Rad Laboratories from $325 to $275, citing updated assumptions that now reflect slightly higher discount rates, a lower revenue growth outlook, a modestly adjusted profit margin, and a recalibrated future P/E multiple. What’s in the News for Bio-Rad Laboratories On May 18, 2026, Elliott Investment Management LP disclosed a significant stake in Bio-Rad Laboratories and publicly called for steps to improve the company’s share price, citing what it described as more than a 70% decline from a peak in late 2021.내러티브 업데이트 • Jun 18
BIO: Activist Campaign And Ongoing Buybacks Will Drive Future Share Price
Analysts have kept their $320 price target on Bio-Rad Laboratories steady, citing only modest adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions that offset each other in their valuation models. What’s in the News for Bio-Rad Laboratories On May 18, 2026, Elliott Investment Management LP disclosed a significant stake in Bio-Rad Laboratories and called for actions aimed at raising the share price, citing what it describes as more than a 70% decline from a peak in late 2021.내러티브 업데이트 • Jun 04
BIO: Activist Pressure And Buybacks Will Shape Future Value Realization
Analysts have reaffirmed their $320.00 price target for Bio-Rad Laboratories, citing adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E as the main factors behind the updated view. What's in the News Activist investor Elliott Investment Management has taken a significant stake in Bio-Rad Laboratories after the stock declined more than 70% from its late 2021 peak, and is publicly pushing for improvements in the share price and company performance.내러티브 업데이트 • May 15
BIO: Share Repurchases Will Support Future Upside Despite Lower Margin Outlook
Analysts have trimmed their price target on Bio-Rad Laboratories from $321.25 to $293.00, reflecting updated views on growth, margins, discount rate, and future P/E assumptions. What's in the News From January 1, 2026 to March 31, 2026, Bio-Rad Laboratories repurchased 176,257 shares for US$47.42 million, equal to 0.65% of its shares.내러티브 업데이트 • Apr 29
BIO: Completed Buybacks And Intangible Impairment Will Support Future Upside
Analysts maintained their $320.00 price target for Bio-Rad Laboratories, making only minor adjustments to assumptions for discount rate, revenue, profit margin, and future P/E ratio to support this unchanged outlook. What's in the News Reported impairment charges of purchased intangibles and related items of $172.8 million for the fourth quarter ended December 31, 2025 (Key Developments).내러티브 업데이트 • Apr 15
BIO: Buybacks And Intangible Impairment Will Shape Balanced Forward Expectations
Analysts have reset their price target on Bio-Rad Laboratories from $375 to $320, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E expectations. What's in the News Completed share repurchase of 2,614,132 shares, representing 9.26% of outstanding shares, for a total of US$715.43 million under the buyback program announced on July 20, 2023 (Key Developments).내러티브 업데이트 • Mar 31
BIO: Share Repurchase And Higher Margin Outlook Will Support Future Upside
Analysts have reduced their price target on Bio-Rad Laboratories from $348.00 to $321.25, reflecting updated assumptions for revenue growth, profit margins, discount rate and future P/E that result in a slightly more conservative valuation framework. What's in the News Completed share repurchase of 2,614,132 shares, representing 9.26% of outstanding shares, for a total of US$715.43m under the buyback that was announced on July 20, 2023 (Key Developments).내러티브 업데이트 • Mar 17
BIO: Share Repurchases And Intangible Impairment Will Shape Future Upside
Analysts have maintained their $375.00 price target for Bio-Rad Laboratories, citing only minor adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E to reflect updated model inputs rather than a change in their overall view. What's in the News Completed share repurchase of 2,614,132 shares, representing 9.26% of outstanding shares, for a total of US$715.43m under the buyback announced on July 20, 2023 (Key Developments).내러티브 업데이트 • Mar 03
BIO: Share Repurchases And Margin Outlook Will Support Future Upside
Analysts have maintained their price target for Bio-Rad Laboratories at $375, citing updated assumptions that include slightly higher revenue, improved profit margins, and a lower future P/E multiple, which together support the unchanged assessment of fair value. What's in the News From October 1, 2025 to December 31, 2025, Bio-Rad Laboratories reported no additional share repurchases, with 0 shares bought for $0, under its existing buyback program (Key Developments).내러티브 업데이트 • Feb 17
BIO: Share Repurchases Will Support Future Upside Despite Impairment Charges
Analysts are keeping their price target for Bio-Rad Laboratories steady at $375, with updated assumptions that include a slightly higher discount rate, a higher revenue growth outlook, a lower profit margin, and a higher future P/E multiple to reflect their latest view of the risk and return profile. What's in the News Completed share repurchase of 2,614,132 shares, representing 9.26% of the company, for a total of US$715.43 million under the buyback announced on July 20, 2023 (Key Developments).내러티브 업데이트 • Feb 03
BIO: Fair Outlook Will Balance Richer Margins Against Higher Required Returns
Analysts have lifted their price target on Bio-Rad Laboratories from US$265 to US$325, reflecting updated views on slightly different growth assumptions, a higher projected profit margin, and an adjusted future P/E multiple. Valuation Changes Fair Value: updated from US$265 to US$325, indicating a higher implied valuation level.내러티브 업데이트 • Jan 20
BIO: Share Buybacks And Oncology Assay Partnership Will Drive Future Upside
Analysts have kept their price target for Bio-Rad Laboratories broadly steady at about US$375.00, reflecting only slight adjustments to modeled discount rate, revenue growth, profit margin, and future P/E assumptions in their updated views. What's in the News From July 1, 2025 to September 30, 2025, Bio-Rad repurchased 212,578 shares, about 0.79% of its shares, for US$52.83 million under its existing buyback program.분석 기사 • Jan 06
Estimating The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Key Insights Bio-Rad Laboratories' estimated fair value is US$394 based on 2 Stage Free Cash Flow to Equity Current...내러티브 업데이트 • Jan 06
BIO: Share Buybacks And Oncology Partnership Will Support Future Upside
Analysts have lowered their price target on Bio-Rad Laboratories from US$437 to US$375, based on updated assumptions that combine more moderate revenue growth expectations with a slightly higher discount rate and a lower future P/E, partially offset by a higher projected profit margin. What's in the News Completed share repurchase of 2,614,132 shares, or 9.26% of the company, for a total of US$715.43m under the buyback announced on July 20, 2023 (Key Developments).내러티브 업데이트 • Dec 14
BIO: Share Repurchase Will Drive Attractive Shareholder Returns Ahead
Narrative Update on Bio-Rad Laboratories Analysts have reaffirmed their conviction in Bio-Rad Laboratories, with the price target effectively unchanged at approximately 348 dollars. Modest tweaks to the discount rate, long-term revenue growth, profit margin, and future valuation assumptions largely offset one another in updated models.내러티브 업데이트 • Nov 28
BIO: Share Repurchase and Expanded Partnership Will Shape Performance in Coming Quarters
Analysts have maintained their price target for Bio-Rad Laboratories at $348.00, noting only minor adjustments to revenue growth and profit margin expectations this quarter. What's in the News Bio-Rad Laboratories completed the repurchase of 2,614,132 shares, representing 9.26% of outstanding shares, for $715.43 million under a buyback program announced in July 2023.내러티브 업데이트 • Nov 14
BIO: Share Repurchase and Expanded Partnerships Will Influence Future Performance
Analysts have raised their price target for Bio-Rad Laboratories from $324 to $348. They cite updated financial assumptions as well as small shifts in projected growth rates and profitability.내러티브 업데이트 • Oct 30
BIO: Expanded Diagnostics Partnership Will Drive Margin Improvements Amid Mixed Revenue Outlook
Analysts have raised their price target for Bio-Rad Laboratories from $310 to $324, reflecting updated profit margin estimates. These changes more than offset slightly lower revenue growth expectations.내러티브 업데이트 • Sep 28
Molecular Diagnostics Expansion Will Unlock Potential While Cost Challenges Persist
The decline in Bio-Rad Laboratories’ consensus price target to $310.00 primarily reflects lower future P/E and revenue growth expectations. What's in the News Completed buyback of 2,401,554 shares (8.47% of outstanding) for $662.6 million under program announced July 2023.새로운 내러티브 • May 13
Acquisition And Droplet Digital PCR Will Advance Oncology Diagnostics
Bio-Rad's efforts in digital PCR technology and strategic acquisitions aim to expand applications and bolster revenue through oncology diagnostics and rare mutation detection.Seeking Alpha • Jan 29
Bio-Rad: Uncertainties And Conservatism Continue To Hold Stock Back From Its Full Potential
Summary Bio-Rad has been challenged by tough end-market conditions in life sciences tools, but the outlook for 2025 is better. The company's cautious approach has led to lackluster sales growth and margin leverage over the long term, and there are only a handful of meaningful revenue drivers with above-average potential. I believe BIO management has long been too conservative and unfocused with its R&D spending, but recent commentary suggests that growth potential and ROI will play a bigger role going forward. Bio-Rad's stake in Sartorius remains a significant store of value, but management's long-term plans remain unclear. While undervalued and having potential for longer-term growth upside, I remain cautious due to management and strategic concerns, as well as a large reliance on Sartorius to drive overall value. Read the full article on Seeking AlphaSeeking Alpha • Nov 25
Why Bio-Rad Laboratories Is Overvalued: A Fundamental And DCF Analysis
Summary Bio-Rad is filing fewer patents year after year, which suggests that it is struggling to innovate and develop new products and services. The company is lagging its peers with a negative ROE, and net sales are expected to decline in 2024. Valuing Bio-Rad using a discounted cash flow model indicates that the BIO stock is overvalued by 20.10%. Read the full article on Seeking AlphaSeeking Alpha • Sep 23
Bio-Rad Laboratories: Overvalued Given Current Growth Prospects
Summary Bio-Rad Laboratories is buying back a considerable amount of its own stock given the shares' current valuation and growth prospects. Profits and sales are expected to rebound in FY2025. A fuller look at Bio-Rad Laboratories is provided in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Jul 14
Bio-Rad: Economics Unsupportive With Capital Valued 70 Cents On The Dollar
Summary Bio-Rad Laboratories, Inc. is a multinational manufacturer and distributor of life science research and clinical diagnostics products. The company's stock has been underperforming due to various pressures, including its position in Sartorius AG. Despite potential catalysts like product launches, the stock is considered overvalued with weak returns on capital and declining margins. Read the full article on Seeking AlphaSeeking Alpha • Apr 14
Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker
Summary Bio-Rad is a "picks and shovels" company in the life sciences industry, but lacks standout growth, margins, or returns, and that has been largely true for more than two decades. Recent trends in the life sciences space have been challenging, driving, double-digit declines in Bio-Rad's Life Sciences segment, and neither biopharma nor academic/government budgets look great for 2024. Bio-Rad's holdings in Sartorius bring significant value to the company, but Sartorius shares have sold off considerably since the bioproduction bubble popped and investor enthusiasm has faded. There's an interesting some-of-the-parts story here, particularly if bioproduction growth resumes after a period of capacity digestion, but it's hard to love Bio-Rad on a standalone basis. Read the full article on Seeking AlphaCEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$222m |
| Mar 31 2026 | n/a | n/a | US$169m |
| Dec 31 2025 | US$8m | US$1m | US$760m |
| Sep 30 2025 | n/a | n/a | -US$676m |
| Jun 30 2025 | n/a | n/a | US$319m |
| Mar 31 2025 | n/a | n/a | -US$2b |
| Dec 31 2024 | US$8m | US$1m | -US$2b |
| Sep 30 2024 | n/a | n/a | -US$779m |
| Jun 30 2024 | n/a | n/a | -US$1b |
| Mar 31 2024 | n/a | n/a | -US$322m |
| Dec 31 2023 | US$7m | US$1m | -US$637m |
| Sep 30 2023 | n/a | n/a | -US$159m |
| Jun 30 2023 | n/a | n/a | -US$428m |
| Mar 31 2023 | n/a | n/a | -US$191m |
| Dec 31 2022 | US$8m | US$1m | -US$4b |
| Sep 30 2022 | n/a | n/a | -US$6b |
| Jun 30 2022 | n/a | n/a | -US$2b |
| Mar 31 2022 | n/a | n/a | -US$91m |
| Dec 31 2021 | US$9m | US$988k | US$4b |
| Sep 30 2021 | n/a | n/a | US$7b |
| Jun 30 2021 | n/a | n/a | US$4b |
| Mar 31 2021 | n/a | n/a | US$4b |
| Dec 31 2020 | US$8m | US$987k | US$4b |
| Sep 30 2020 | n/a | n/a | US$4b |
| Jun 30 2020 | n/a | n/a | US$2b |
| Mar 31 2020 | n/a | n/a | US$2b |
| Dec 31 2019 | US$7m | US$950k | US$2b |
보상 대 시장: Norman의 총 보수(USD8.00M)는 US 시장에서 비슷한 규모 기업의 평균(USD14.74M)보다 낮습니다.
보상과 수익: Norman의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Norman Schwartz (76 yo)
23.7yrs
재임 기간
US$7,995,841
보수
Mr. Norman D. Schwartz has been the Chief Executive Officer of Bio-Rad Laboratories, Inc. since January 1, 2003 and has been its Chairman since 2012. Mr. Schwartz was Principal Financial Officer of Bio-Rad...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Chairman & CEO | 23.7yrs | US$8.00m | 4.58% $ 450.8m | |
| President & COO | 2yrs | US$3.68m | 0.0073% $ 722.0k | |
| Executive VP & CFO | 2.4yrs | US$2.99m | 0.016% $ 1.5m | |
| Executive VP & President of Life Science Group | no data | US$2.61m | 0.0076% $ 744.6k | |
| Executive Vice President of Global Commercial Operations | 1.1yrs | US$2.99m | 0.0046% $ 453.5k | |
| Vice President of Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| Senior VP and Chief Compliance & Privacy Officer | no data | 데이터 없음 | 데이터 없음 | |
| Executive VP | 2.7yrs | 데이터 없음 | 0.0062% $ 607.9k | |
| Executive Vice President of Global Human Resources | no data | 데이터 없음 | 데이터 없음 | |
| Executive Vice President of Global Commercial Operations | 11.8yrs | US$2.24m | 0.031% $ 3.0m | |
| Senior Vice President of Global Technology & Systems | no data | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Marketing at Life Science Group | no data | 데이터 없음 | 데이터 없음 |
2.5yrs
평균 재임 기간
55yo
평균 나이
경험이 풍부한 관리: BIO의 경영진은 경험이 있음으로 간주됩니다(평균 재임 2.5 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Chairman & CEO | 31.7yrs | US$8.00m | 4.58% $ 450.8m | |
| Lead Independent Director | 9.4yrs | US$337.71k | 0.0045% $ 446.6k | |
| Independent Director | 9.4yrs | US$324.71k | 0.0027% $ 262.6k | |
| Independent Director | 9.4yrs | US$309.71k | 0.0027% $ 262.6k | |
| Independent Director | 9.4yrs | US$329.71k | 0.0027% $ 262.6k | |
| Director | 4.4yrs | 데이터 없음 | 0.021% $ 2.1m |
9.4yrs
평균 재임 기간
67.5yo
평균 나이
경험이 풍부한 이사회: BIO의 이사회는 경험이 있음으로 간주됩니다(평균 재임 9.4 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/09/15 01:53 |
| 종가 | 2026/09/15 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Bio-Rad Laboratories, Inc.는 20명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Jon Wood | BofA Global Research |
| Yuan Zhi | B. Riley Securities, Inc. |
| Patrick Donnelly | Citigroup Inc |